EDUCATIONAL WEBINAR: Evidence-Based Strategy in the Prevention of Complications due to Retained Blood
An Educational Webinar with Presenters: Marc Gillinov, MD, Marc Gerdisch, MD, and Alyson Mehringer, RN discussing the basic principles of Chest Tube Management, the results of a 1 year quality improvement study and the operational perspective from the ICU Nursing Staff.
Washington, DC.—October 10, 2014—ClearFlow Inc., a medical device company based in Anaheim, CA, today announced positive results from the Prevention of Retained Blood Outcomes Using Active Clearance Technology trial, (PRO-ACT), a clinical study evaluating the use of PleuraFlow® Active Clearance Technology™ System to prevent retained blood complications. The PleuraFlow System enables caregivers to actively keep chest drainage tubes clear of clot in the early hours after heart surgery.
On Friday, October 10th investigators will report clinical trial results from the Prevention of Retained Blood Outcomes with Active Clearance Technology (PROACT) assessing the use of PleuraFlow to reduce Retained Blood Complications after Cardiac Surgery at FACTS-Care CVT 2014 in Washington, D.C. This is one of the largest studies to assess outcomes with Active Clearance Technology to reduce complications after heart surgery.
Anaheim, CA., Oct. 1, 2014 — ClearFlow, Inc., a medical device company based in Anaheim, CA, announced that results from the PRO-ACT trial, (Prevention of Retained Blood Outcomes Using Active Clearance Technology), a clinical study evaluating the use of PleuraFlow® Active Clearance Technology™ System to prevent Retained Blood Complications (RBC) will be presented at the upcoming Cardiovascular-Thoracic (CVT) Critical Care meeting in Washington, D.C. next week.
Toronto, Canada—May 5, 2014—Distinguished physicians from leading cardiac surgery centers gathered at an Educational Symposium to share their experiences with a new-generation blood evacuation system for use following cardiothoracic surgical procedures. ClearFlow, Inc. hosted the Symposium at the recent American Association of Thoracic Surgeon’s meeting in Toronto, Canada, where their award-winning technology was on exhibit for over 2,400 cardiac surgeons and healthcare professionals.
Anaheim, California. ClearFlow Inc., a venture-funded designer and manufacturer of PleuraFlow® Active Clearance Technology™, a new generation blood evacuation system for use following cardiothoracic surgical procedures is pleased to announce that Mr. Michael Cox has joined the Company as Vice President of Sales, North America.
We are excited to announce that Clear Catheter Systems, Inc. is now ClearFlow, Inc. Our mission is to develop the best devices to proactively drain blood and fluids after surgery.
Interest in Clear Catheter System Inc. continues to spike after three strong meetings in Canada aimed at educating cardiac surgeons about PleuraFlow® Active Clearance Technology®, its positive impact in reducing complications related to Retained Blood and Fluids, and improving patient outcomes as well as reducing hospital costs.
2013 “Innovations in Cardiovascular Interventions” Top Prize goes to Medical Device Start-up for PleuraFlow Clear Catheter Systems, Inc., announced today it has won the 2013 Innovations in Cardiovascular Interventions (ICI) Best Start-Up Innovation Award for its medical device, PleuraFlow®, a novel system that optimally evacuates blood and fluid after surgery to speed recovery and improve patient outcomes in the ICU during the initial critical hours after heart surgery.